These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 28484463)

  • 1. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
    Hughes A; Yong ASM
    Front Immunol; 2017; 8():469. PubMed ID: 28484463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
    Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-free remission and immunity in chronic myeloid leukemia.
    Ureshino H
    Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
    Kumagai T
    Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.
    Hsieh YC; Kirschner K; Copland M
    Leukemia; 2021 May; 35(5):1229-1242. PubMed ID: 33833387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of cancer immunology in chronic myelogenous leukemia.
    Ureshino H; Shindo T; Kimura S
    Leuk Res; 2020 Jan; 88():106273. PubMed ID: 31765938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allelic polymorphisms of
    Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S
    Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia.
    Han JJ
    Blood Res; 2023 Apr; 58(S1):S58-S65. PubMed ID: 37026381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
    Irani YD; Hughes A; Clarson J; Kok CH; Shanmuganathan N; White DL; Yeung DT; Ross DM; Hughes TP; Yong ASM
    Br J Haematol; 2020 Nov; 191(3):433-441. PubMed ID: 32352166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia.
    Fujioka Y; Sugiyama D; Matsumura I; Minami Y; Miura M; Atsuta Y; Ohtake S; Kiyoi H; Miyazaki Y; Nishikawa H; Takahashi N
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic myeloid leukemia and NK cell immunity].
    Ureshino H; Shindo T; Tanaka H; Kimura S
    Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients.
    Etienne G; Dulucq S; Bauduer F; Adiko D; Lifermann F; Dagada C; Lenoir C; Schmitt A; Klein E; Madene S; Fort MP; Bijou F; Moldovan M; Turcq B; Robbesyn F; Durrieu F; Versmée L; Katsahian S; Faberes C; Lascaux A; Mahon FX
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899879
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
    Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
    Front Immunol; 2018; 9():2587. PubMed ID: 30487792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.
    Xu Z; Yin J; Sun Q; Hu J; Hong M; Qian S; Liu W
    Leuk Lymphoma; 2022 Nov; 63(11):2616-2626. PubMed ID: 35758278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.
    Irani YD; Kok CH; Clarson J; Shanmuganathan N; Branford S; Yeung DT; Ross DM; Hughes TP; Yong ASM
    Blood Adv; 2023 Jun; 7(11):2364-2374. PubMed ID: 36622326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
    Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
    Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
    Mahon FX; Etienne G
    Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia.
    Annunziata M; Bonifacio M; Breccia M; Castagnetti F; Gozzini A; Iurlo A; Pregno P; Stagno F; Specchia G
    Front Oncol; 2020; 10():883. PubMed ID: 32582549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.
    Iurlo A; Cattaneo D; Consonni D; Castagnetti F; Miggiano MC; Binotto G; Bonifacio M; Rege-Cambrin G; Tiribelli M; Lunghi F; Gozzini A; Pregno P; Abruzzese E; Capodanno I; Bucelli C; Pizzuti M; Artuso S; Iezza M; Scalzulli E; La Barba G; Maggi A; Russo S; Elena C; Scortechini AR; Tafuri A; Latagliata R; Caocci G; Bocchia M; Galimberti S; Luciano L; Fava C; Foà R; Saglio G; Rosti G; Breccia M
    Front Pharmacol; 2023; 14():1154377. PubMed ID: 37033642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.